Paraneoplastic Jaw Dystonia and Laryngospasm With Antineuronal Nuclear Autoantibody Type 2 (Anti-Ri)
Authors:
- Sean J. PittockSPSean J. Pittock
- Joseph E. ParisiJPJoseph E. Parisi
- Andrew McKeonAMAndrew McKeon
- Shanu F. RoemerSRShanu F. Roemer
- Claudia F. LucchinettiCLClaudia F. Lucchinetti
- K. Meng TanKTK. Meng Tan
- B. Mark KeeganBKB. Mark Keegan
- Samuel F. HunterSHSamuel F. Hunter
- Paul R. DuncanPDPaul R. Duncan
- Joachim M. BaehringJBJoachim M. Baehring
- Joseph Y. MatsumotoJMJoseph Y. Matsumoto
- Vanda A. LennonVLVanda A. Lennon
Open Access
- 1 September 2010
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 67 (9) , 1109-1115
Abstract
Despite its rarity among paraneoplastic autoantibodies recognized in clinical practice, antineuronal nuclear antibody type 2 (ANNA-2, also known as anti-Ri) is one of the most common serologic tests ordered in evaluating patients suspected of having a paraneoplastic neurologic disorder.1-3 ANNA-2 is more common in women than in men and is a marker of neurologic autoimmunity initiated by carcinoma of the breast or lung. Other cancer associations have been reported, including carcinomas of fallopian tube, ovary, bladder, and gastric neuroendocrine cells, as well as seminoma and carcinoid tumor.3-10 Two central nervous system neuronal proteins, 53 to 61 kDa and 79 to 94 kDa, account for ANNA-2 immunoreactivity.1 The smaller antigen, Nova, is a highly conserved RNA-binding nuclear protein,11,12 which is expressed in brainstem and ventral spinal cord in embryonic mice and adult rats.11-13 Paraneoplastic opsoclonus-myoclonus syndrome is commonly presumed to be synonymous with ANNA-2–related autoimmunity. However, in a review of clinical accompaniments among 34 patients with ANNA-2 seropositivity identified in the Mayo Clinic Neuroimmunology Laboratory, Rochester, Minnesota,3 only 10 of 28 patients (35%) for whom clinical information were available had opsoclonus-myoclonus syndrome. ANNA-2 is associated with multifocal dysfunction of brainstem, cerebellum, and spinal cord.1,14 The 2003 article mentioned jaw dystonia and laryngospasm as novel but surprisingly common and severe accompaniments of ANNA-2.3Keywords
This publication has 15 references indexed in Scilit:
- Anti–Ri antibodies and limbic encephalitis in a patient with carcinoid tumour of the lungJournal of Neurology, 2005
- Anti‐neuronal nuclear autoantibody type 2: Paraneoplastic accompanimentsAnnals of Neurology, 2003
- Anti-Ri-associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinomaCancer, 2001
- Anti-Ri positive opsoclonus-myoclonus-ataxia in ovarian duct cancerJournal of Neurology, 1998
- Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patientsJournal of Neurology, 1997
- The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodiesJournal of Neuroscience, 1996
- The expression of a neuronal nuclear antigen (Ri) recognized by the human anti-Ri autoantibody in the developing rat nervous systemNeuroscience Letters, 1993
- Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor systemNeuron, 1993
- Anti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancerAnnals of Neurology, 1991
- An antineuronal autoantibody in paraneoplastic opsoclonusAnnals of Neurology, 1988